Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $485.7 million.

  • Nurix Therapeutics' Cash from Financing Activities fell 97.48% to $1.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $203.2 million, marking a year-over-year decrease of 28.76%. This contributed to the annual value of $485.7 million for FY2024, which is 14996.89% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Cash from Financing Activities of $485.7 million as of FY2024, which was up 14,996.89% from $3.2 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Cash from Financing Activities peaked at $485.7 million during FY2024, and registered a low of $3.2 million during FY2023.
  • In the last 3 years, Nurix Therapeutics' Cash from Financing Activities had a median value of $117.2 million in 2022 and averaged $202.0 million.
  • Per our database at Business Quant, Nurix Therapeutics' Cash from Financing Activities surged by 268,966.67% in 2020 and then tumbled by 97.25% in 2023.
  • Nurix Therapeutics' Cash from Financing Activities (Yearly) stood at $339.0 million in 2020, then tumbled by 54.61% to $153.9 million in 2021, then decreased by 23.84% to $117.2 million in 2022, then crashed by 97.25% to $3.2 million in 2023, then skyrocketed by 14,996.89% to $485.7 million in 2024.